Cargando…

A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard

BACKGROUND: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. METHODS AND FINDINGS...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmucker, Christine, Ehlken, Christoph, Agostini, Hansjuergen T., Antes, Gerd, Ruecker, Gerta, Lelgemann, Monika, Loke, Yoon K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411814/
https://www.ncbi.nlm.nih.gov/pubmed/22880086
http://dx.doi.org/10.1371/journal.pone.0042701